Senior Principal Scientist, Bispecifics & Antibody Engineering
Regeneron Pharmaceuticals
Summary
At Regeneron, we use science and innovation to develop life-changing medicines for people with serious diseases. We are seeking a Senior Principal Scientist to lead a small team within our Bispecific Antibodies group, using structural insight to design, engineer, and optimize next-generation bispecific and multispecific antibody therapeutics. In this role, you will integrate structural data with AI/ML-enabled design and high-throughput, automated experimental validation, co-championing programs with biology leads from concept to IND.
Job description
Discover your role:
- Set molecular design strategy for bispecific and multispecific antibodies based on target biology, structure, and mechanism of action
- Lead structure-guided design of novel formats, including binding-arm selection, epitope and geometry optimization, and chain pairing, using tools such as AlphaFold, Rosetta, MOE, and PyMOL
- Drive protein engineering campaigns that integrate AI/ML and in silico design into iterative design-build-test-learn cycles with computational partners
- Oversee high-throughput construct generation, expression, purification, biophysical characterization, and cell-based functional assays to rank molecules on activity and developability
- Build curated engineering datasets and design rules that strengthen the bispecific platform across oncology, immunology, and infectious disease
- Lead, mentor, and develop a team of scientists, partnering with internal and external groups to advance the pipeline
- Apply structural biology to solve hard antibody and protein engineering problems, combining experimental data with computational and AI/ML-driven design
- Lead multiple projects in parallel with strong organization and flexibility, communicating structural insights clearly to non-specialist audiences
This role requires:
- Ph.D. in Structural Biology, Biochemistry, Biophysics, Protein Engineering, Computational Biology, Immunology, or a related field
- 8+ years of post-Ph.D. experience, including at least 5 years in the biotech/pharmaceutical industry
- At least 2 years of direct people management experience with a record of success developing scientists
- A record of innovation and research accomplishments in antibody or protein therapeutic engineering (publications, patents, or programs advanced into development)
- Experience engineering bispecific or multispecific antibody formats, with deep hands-on expertise in molecular cloning, protein expression, purification, and biochemical/biophysical characterization
- Experience with mammalian cell culture and cell-based assay development
- Preferred: experience applying computational design and AI/ML tools to protein engineering, and with automated or high-throughput protein engineering workflows
Requirements
- Ph.D. in Structural Biology, Biochemistry, Biophysics, Protein Engineering, Computational Biology, Immunology, or a related field
- 8+ years of post-Ph.D. experience, including at least 5 years in the biotech/pharmaceutical industry
- At least 2 years of direct people management experience with a record of success developing scientists
- A record of innovation and research accomplishments in antibody or protein therapeutic engineering (publications, patents, or programs advanced into development)
- Experience engineering bispecific or multispecific antibody formats, with deep hands-on expertise in molecular cloning, protein expression, purification, and biochemical/biophysical characterization
- Experience with mammalian cell culture and cell-based assay development
- Preferred: experience applying computational design and AI/ML tools to protein engineering, and with automated or high-throughput protein engineering workflows
Benefits
- Annual bonuses
- Equity awards
- Pension or retirement benefits
- 401(k) company match
- Health and wellness programs
- Fitness centers
- Insurance benefits
- Paid time off
- Family support benefits
Company overview
Regeneron Pharmaceuticals is a leading American biotechnology company founded in 1988 and headquartered in Tarrytown, New York. The company specializes in inventing, developing, and commercializing life-transforming medicines for people with serious diseases. Regeneron is renowned for its innovative antibody technologies and has developed several groundbreaking therapies, including EYLEA® for retinal diseases, DUPIXENT® for inflammatory conditions, and the COVID-19 antibody cocktail REGEN-COV®. The company operates with a strong focus on research and development across multiple therapeutic areas including ophthalmology, oncology, cardiovascular diseases, and rare genetic disorders. Regeneron's proprietary VelocImmune® technology platform enables the rapid generation of fully human monoclonal antibodies. With over 15,000 employees globally and annual revenues exceeding $14 billion, Regeneron has established itself as a major force in the biotechnology industry, consistently ranking among the top-performing pharmaceutical companies and maintaining a robust pipeline of investigational therapies.